Printer Friendly

FDA REQUESTS ADDITIONAL INFORMATION ON ORTHOLOGIC CORP. PMA

 PHOENIX, June 21 /PRNewswire/ -- OrthoLogic (NASDAQ-NMS: OLGC), a medical device manufacturer, said today that the Food & Drug Administration (FDA) has requested additional information, as part of its review of the company's premarket approval application (PMA) for the company's OrthoLogic 1000 bone growth stimulator. The PMA, which was accepted for filing with a filing date of November 1991, seeks approval for marketing and use of the non-invasive device for the treatment of non-healing (non-union) fractures.
 Allan Weinstein, Ph.D., OrthoLogic president and chief executive officer, said "We intend to provide the FDA with the information required to complete their review, as soon as possible, and we are hopeful that the approval process will move forward expeditiously." Initial GMP inspection of OrthoLogic's manufacturing facilities, as part of the PMA review process, were completed in November 1992. No deficiencies were noted.
 OrthoLogic is currently conducting additional clinical trials of the OrthoLogic 1000 related to use of the device for the treatment of other types of problem bone fractures, and recently initiated clinical trials of a similar product, the SpinaLogic 1000, for use as an adjunct to spinal fusion surgery.
 OrthoLogic is a developer of technologically advanced orthopaedic trauma products that enhance healing of musculoskeletal tissues. The company was founded in 1987 and is headquartered in Phoenix.
 -0- 6/21/93
 /CONTACT: Allan M. Weinstein, president and CEO of OrthoLogic Corp., 602-437-5520; or Lee Feldman of Peters & Feldman, 203-972-1201, for OrthoLogic/
 (OLGC)


CO: OrthoLogic Corp. ST: California IN: MTC SU:

EH -- LA014 -- 3980 06/21/93 10:29 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 21, 1993
Words:255
Previous Article:POLYGRAM RECORDS FILES TRADEMARK INFRINGEMENT SUIT AGAINST RECORDING GROUP VERVE
Next Article:HANNAFORD REPORTS SALES FOR MAY
Topics:


Related Articles
IMRE ANNOUNCES PMA EXPEDITED REVIEW
MOLECULAR BIOSYSTEMS RECEIVES FDA LETTER REGARDING ALBUNEX(R) PMA AMENDMENT
ORTHOLOGIC CORP. RESPONDS TO FDA REQUEST FOR ADDITIONAL INFORMATION ON PMA APPLICATION
ORTHOLOGIC RECEIVES APPROVABLE LETTER FROM FDA FOR BONE GROWTH STIMULATOR
MBI DELIVERS UPDATE ON ALBUNEX
FDA REQUESTS ADDITIONAL INFORMATION ON DATASCOPE'S VASOSEAL PMA
OrthoLogic Submits PMA Supplement for the SpinaLogic-1000
OrthoLogic Announces SpinaLogic-1000 PMA Supplement Accepted for Filing by FDA.
OrthoLogic Reports Third Quarter Results.
OrthoLogic Submits Amendment to SpinaLogic PMA Supplement.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters